media reports
Expanding into ASEAN: U-NEURON Partners with Malaysia’s SBC
Collaborating on Amniotic Fluid Stem Cell Clinical Applications and Research; Full Line of Nutritional Products Scheduled for Market Launch in 2025
U-NEURON’s ED Drug UA002 Validates Phase 1 Safety Profile
U-NEURON (6973), a biotech companylistedon Taiwan’s Emerging Stock Market, announced on the 3rd that Phase 1 clinical trial enrollment for its novel therapeutic UA002, targeting male erectile dysfunction (ED), has been completed, with Phase 2 trials set to commence.